Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APRE Aprea Therapeutics, Inc.

Trading 11-26 09:45:47 EST

3.08

+0.17

+5.75%

High3.08	Low2.88	Vol1.97K
Open2.88	D1 Closing2.91	Amplitude6.78%
Mkt Cap16.73M	Tradable Cap12.25M	Total Shares5.43M
T/O5.75K	T/O Rate0.05%	Tradable Shares3.98M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"APRE","market":"US","secType":"STK","nameCN":"Aprea Therapeutics, Inc.","latestPrice":3.0774,"timestamp":1732632030931,"preClose":2.91,"halted":0,"volume":1970,"delay":0,"floatShares":3980266,"shares":5434903,"eps":-2.726005,"marketStatus":"Trading","change":0.1674,"latestTime":"11-26 09:45:47 EST","open":2.88,"high":3.0774,"low":2.88,"amount":5752.978392,"amplitude":0.067835,"askPrice":3.12,"askSize":1172,"bidPrice":2.9,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.726005,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732654800000},"marketStatusCode":2,"adr":0,"listingDate":1570075200000,"exchange":"NASDAQ","adjPreClose":2.91,"postHourTrading":{"tag":"盘后","latestPrice":2.91,"preClose":2.91,"latestTime":"16:00 EST","volume":83,"amount":241.53,"timestamp":1732568402395},"volumeRatio":5.914513,"impliedVol":3.9995,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/APRE/wiki","defaultTab":"wiki","newsList":[{"id":"2484562458","title":"Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2484562458","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484562458?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:51","pubTimestamp":1731934260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APRE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2024 07:51 ET (12:51 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","LENZ"],"gpt_icon":0},{"id":"2482463320","title":"BRIEF-Aprea Therapeutics - Got Into At The Market Offering Agreement, May Offer & Sell Shares Of Common Stock Of Up To $3 Million From Time To Time - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2482463320","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482463320?lang=en_us&edition=fundamental","pubTime":"2024-11-09 07:25","pubTimestamp":1731108304,"startTime":"0","endTime":"0","summary":"Nov 8 (Reuters) - Aprea Therapeutics Inc   :   * APREA THERAPEUTICS - GOT INTO AT THE MARKET OFFERING AGREEMENT, MAY OFFER & SELL SHARES OF COMMON STOCK OF UP TO $3 MILLION FROM TIME TO TIME - SEC FILINGSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2482481313","title":"Aprea Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482481313","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482481313?lang=en_us&edition=fundamental","pubTime":"2024-11-09 00:31","pubTimestamp":1731083514,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryAprea Therapeutics Inc APRE.OQ reported a quarterly adjusted loss of 64 cents per share for the quarter ende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF2RG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE"],"gpt_icon":0},{"id":"2481904846","title":"Aprea Therapeutics Inc: Cash Runway for at Least Twelve Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904846?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA2LZCMC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2481248901","title":"Aprea Therapeutics Q3 Net Income USD -3.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481248901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481248901?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nPLXF94F76:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2481960081","title":"Pacira (PCRX) Q3 Earnings Beat Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481960081","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481960081?lang=en_us&edition=fundamental","pubTime":"2024-11-07 06:15","pubTimestamp":1730931315,"startTime":"0","endTime":"0","summary":"Pacira  came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.72%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.73 per share when it actually produced earnings of $0.89, delivering a surprise of 21.92%.Pacira , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $167.72 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 0.91%. This compares to year-ago revenues of $163.93 million. The company has topped consensus revenue estimates three times over the last four quarters.Pacira shares have lost about 48.8% since the beginning of the year versus the S&P 500's gain of 21.2%.While Pacira has underperformed the market so far this year, the question that comes","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/t6.OdXEVKQihFo9otNenfg--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/t6.OdXEVKQihFo9otNenfg--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pacira-pcrx-q3-earnings-beat-221515889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["APRE","PCRX"],"gpt_icon":0},{"id":"2477568799","title":"Insider Spends US$132k Buying More Shares In Aprea Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2477568799","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477568799?lang=en_us&edition=fundamental","pubTime":"2024-10-24 02:43","pubTimestamp":1729709018,"startTime":"0","endTime":"0","summary":"Potential Aprea Therapeutics, Inc.  shareholders may wish to note that the Independent Director, Marc Duey, recently bought US$132k worth of stock, paying US$4.39 for each share. That's a very decent purchase to our minds and it grew their holding by a solid 14%.Aprea Therapeutics Insider Transactions Over The Last Year. The recent insider purchases are heartening. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Aprea Therapeutics insiders are expecting a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To help with this, we've discovered 6 warning signs (1 can't be ignored!) that you ought to be aware of before buying any shares in Ap","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-spends-us-132k-buying-184338838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","APRE","LENZ"],"gpt_icon":0},{"id":"2477047531","title":"Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations","url":"https://stock-news.laohu8.com/highlight/detail?id=2477047531","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477047531?lang=en_us&edition=fundamental","pubTime":"2024-10-23 22:20","pubTimestamp":1729693247,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics  shares down about 4% after preliminary safety results from early stage study of single-agent APR-1051 in advanced solid tumors harboring cancer-associated gene alterations. The dose escalation part of the study is currently ongoing and is expected to include up to 39 patients with advanced solid tumors.  Preliminary results demonstrated that APR-1051 is safe and well-tolerated with no hematologic toxicity. There were no signs of neutropenia, with white blood cells and neutrophils trending up for both patients during the first treatment cycle. All adverse events recorded were Grade 1 and 2, with one Grade 1 AE  possibly related to APR-1051. Three patients have been dosed to date with data available on two of these. One had disease progression at 49 days, a second withdrew following 36 days of treatment and dosing is ongoing in the third patient. Source: Press Release","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277229026/image_1277229026.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277229026/image_1277229026.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4195508-aprea-therapeutics-falls-on-data-from-apr-1051-study-in-cancer-associated-gene-alterations","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2477584607","title":"Aprea Therapeutics presents preliminary results on APR-1051","url":"https://stock-news.laohu8.com/highlight/detail?id=2477584607","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477584607?lang=en_us&edition=fundamental","pubTime":"2024-10-23 20:40","pubTimestamp":1729687225,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics (APRE) announced that preliminary safety results on its WEE1 inhibitor APR-1051 are highlighted in a poster being presented toda...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-presents-preliminary-results-on-apr-1051?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-presents-preliminary-results-on-apr-1051?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APR","APRE","BK4196","LENZ","BK4139"],"gpt_icon":0},{"id":"2468464099","title":"Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing","url":"https://stock-news.laohu8.com/highlight/detail?id=2468464099","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468464099?lang=en_us&edition=fundamental","pubTime":"2024-09-20 20:35","pubTimestamp":1726835700,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept. 20, 2024  -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum held September 19th are now available for online viewing. This event was co-sponsored by Zacks Small-Cap Research.The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company’s resource section.Select companies are accepting 1x1 management meeting requests through September 24th.Virtual Investor Conferences  is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.Providing a real-time investor engagement solution, the VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect w","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/life-sciences-virtual-investor-forum-123500670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4179","TQQQ","UNCY","BVAXF","BK4139","FET","SQQQ","PLX","CHRO","EVAX","QLD","NQmain","AEMD","PSQ","MNQmain","QID","ADAP",".IXIC","ACST","GENFF","VNRX","APRE","BK4007"],"gpt_icon":1},{"id":"2468847137","title":"Life Sciences Virtual Investor Forum Agenda Announced for September 19th","url":"https://stock-news.laohu8.com/highlight/detail?id=2468847137","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468847137?lang=en_us&edition=fundamental","pubTime":"2024-09-17 00:07","pubTimestamp":1726502820,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept. 16, 2024  -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held September 19th. This event is co-sponsored by Zacks Small-Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend.It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.“We’re looking forward to bringing the latest innovators together at the Life Sciences Virtual Investor Forum this Thursday,” said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. “In collaboration with Zacks Small-Cap Research, this conference will provide an efficient platform for these companies to seamlessly engage their investor base.”Virtual Investor Conferences Contact:John ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/life-sciences-virtual-investor-forum-160700187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHRO","BK4590","EVAX","SQQQ",".IXIC","AEMD","MNQmain","QLD","BK4144","PSQ","BK4561","BK4179","BCLI","PLX","BK4139","BVAXF","APRE","GENFF","BK4585","ADAP","FET","QID","BK4588","NQmain","UNCY","ET","ACST","VNRX","BK4581","TQQQ"],"gpt_icon":1},{"id":"2466742902","title":"Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19","url":"https://stock-news.laohu8.com/highlight/detail?id=2466742902","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466742902?lang=en_us&edition=fundamental","pubTime":"2024-09-12 20:30","pubTimestamp":1726144200,"startTime":"0","endTime":"0","summary":"This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.Management will be available for 1x1 meetings: Monday September 23.Forward-Looking StatementCertain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aprea-therapeutics-present-life-sciences-123000695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["APRE","BK4179","LENZ","FET","BK4139"],"gpt_icon":0},{"id":"2459900513","title":"Aprea Therapeutics Price Target Maintained With a $11.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2459900513","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459900513?lang=en_us&edition=fundamental","pubTime":"2024-08-13 22:44","pubTimestamp":1723560240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APRE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 13, 2024 10:44 ET (14:44 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","APRE"],"gpt_icon":0},{"id":"2459977602","title":"Wedbush Initiates a Buy Rating on Aprea Therapeutics (APRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2459977602","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459977602?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:02","pubTimestamp":1723550557,"startTime":"0","endTime":"0","summary":"In a report released today, Robert Driscoll from Wedbush initiated coverage with a Buy rating on Aprea Therapeutics (APRE – Research Report) and a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-initiates-a-buy-rating-on-aprea-therapeutics-apre?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-initiates-a-buy-rating-on-aprea-therapeutics-apre?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APRE"],"gpt_icon":0},{"id":"2458198054","title":"Analysts Are Bullish on These Healthcare Stocks: Aprea Therapeutics (APRE), TScan Therapeutics (TCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2458198054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458198054?lang=en_us&edition=fundamental","pubTime":"2024-08-12 23:30","pubTimestamp":1723476601,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aprea Therapeutics (APRE – Research Report) and TSca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-aprea-therapeutics-apre-tscan-therapeutics-tcrx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-aprea-therapeutics-apre-tscan-therapeutics-tcrx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4539","TCRX","HCSG","BK4139","APRE"],"gpt_icon":0},{"id":"2458419984","title":"Aprea Therapeutics Inc reports results for the quarter ended in June - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2458419984","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458419984?lang=en_us&edition=fundamental","pubTime":"2024-08-12 22:46","pubTimestamp":1723473975,"startTime":"0","endTime":"0","summary":"* Aprea Therapeutics Inc    reported a quarterly adjusted loss of 58 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -87 cents. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","LENZ"],"gpt_icon":0},{"id":"2458980018","title":"Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2458980018","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458980018?lang=en_us&edition=fundamental","pubTime":"2024-08-12 21:45","pubTimestamp":1723470302,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics, Inc.  came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.38%. A quarter ago, it was expected that this company would post a loss of $0.78 per share when it actually produced a loss of $0.67, delivering a surprise of 14.10%.Aprea Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.56 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 462%. This compares to year-ago revenues of $0.25 million. The company has topped consensus revenue estimates two times over the last four quarters.Aprea Therapeutics shares have lost about 28.5% since the beginning of the year versus the S&P 500's gain of 12%.While Aprea Therapeutics has underperformed the market so far this year, the ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9tpS8u8rAmiEoUItmUZeOA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/090f58c1efbe3555b861102525e50b39","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9tpS8u8rAmiEoUItmUZeOA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/090f58c1efbe3555b861102525e50b39"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aprea-therapeutics-inc-apre-reports-134502478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["APRE"],"gpt_icon":0},{"id":"2458607463","title":"Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2458607463","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458607463?lang=en_us&edition=fundamental","pubTime":"2024-08-12 20:30","pubTimestamp":1723465801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240812:nTUA1XV21W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LENZ","APRE"],"gpt_icon":0},{"id":"2458600344","title":"Aprea Therapeutics Inc - Cash Runway Extended Into Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2458600344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458600344?lang=en_us&edition=fundamental","pubTime":"2024-08-12 20:30","pubTimestamp":1723465801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240812:nTUA1XV21W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LENZ","BK4139","APRE"],"gpt_icon":0},{"id":"2458607101","title":"Aprea Therapeutics Q2 Net Income USD -3.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2458607101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458607101?lang=en_us&edition=fundamental","pubTime":"2024-08-12 20:30","pubTimestamp":1723465801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240812:nPLX6800EB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","USD","LENZ","APRE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aprea.com","stockEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":-0.2868},{"period":"3month","weight":-0.1725},{"period":"6month","weight":-0.3755},{"period":"1year","weight":-0.25},{"period":"ytd","weight":-0.3809}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.060151},{"month":2,"riseRate":0.4,"avgChangeRate":-0.006523},{"month":3,"riseRate":0.4,"avgChangeRate":-0.083115},{"month":4,"riseRate":0,"avgChangeRate":-0.145108},{"month":5,"riseRate":0,"avgChangeRate":-0.155075},{"month":6,"riseRate":0.4,"avgChangeRate":0.033427},{"month":7,"riseRate":0.2,"avgChangeRate":-0.054462},{"month":8,"riseRate":0.4,"avgChangeRate":0.009617},{"month":9,"riseRate":0.4,"avgChangeRate":-0.051894},{"month":10,"riseRate":0.4,"avgChangeRate":0.026808},{"month":11,"riseRate":0.5,"avgChangeRate":-0.089475},{"month":12,"riseRate":0.4,"avgChangeRate":-0.03668}],"exchange":"NASDAQ","name":"Aprea Therapeutics, Inc.","nameEN":"Aprea Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aprea Therapeutics, Inc.,APRE,Aprea Therapeutics, Inc.股票,Aprea Therapeutics, Inc.股票老虎,Aprea Therapeutics, Inc.股票老虎国际,Aprea Therapeutics, Inc.行情,Aprea Therapeutics, Inc.股票行情,Aprea Therapeutics, Inc.股价,Aprea Therapeutics, Inc.股市,Aprea Therapeutics, Inc.股票价格,Aprea Therapeutics, Inc.股票交易,Aprea Therapeutics, Inc.股票购买,Aprea Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}